vious report on Caucasians which suggested the association of the GSTT1 polymorphism with an increased MM risk and no association of CYP1A1 with the MM risk. The associations of polymorphisms of metabolizing enzymes with the risk for MM differed between Koreans and Caucasians, suggesting an ethnic variation in the susceptibility to MM.
Introduction
The incidence of multiple myeloma (MM) shows a marked interethnic variation: it is lowest in the Japanese (1.7/10 5 ) and the Chinese (2.3/10 5 ), intermediate in Caucasians (4.6/10 5 ) and highest in African-Americans (8.2/10 5 ) [1, 2] . The crude annual incidence of MM in Koreans was 0.2/100,000 individuals in the population 10 years ago, and it has increased rapidly to 1/100,000 [3] . MM incidence has increased worldwide, which may be related to environmental pollution. Environmental toxins are metabolized by the biphasic system involving phase I and II xenobiotic enzymes. Phase I enzymes acti-vate environmental toxins to mutagenic electrophilic intermediates, and phase II enzymes detoxify the intermediates by conjugation. Variable activity of phase I and II enzymes among ethnic groups may explain the interethnic difference in susceptibility to MM.
We had previously reported the association of NAD(P)H quinone oxidoreductase (NQO1, a phase I enzyme) polymorphism with a decreased risk for MM in Koreans [4] . NQO1 * 2 (609C 1 T) causes an amino acid substitution from proline to serine and is known to decrease NQO1 enzyme activity [5] . The odds ratio (OR) for NQO1 * 2/ * 2 (the low metabolizer) was 0.24 (95% confidence interval, CI: 0.01-0.68) in Koreans [4] , while a recent study on NQO1 polymorphisms in Caucasians revealed no direct association with the MM risk [6] .
In the present study, we investigated another phase I enzyme, cytochrome P 450 (CYP) 1A1 which metabolizes polycyclic aromatic hydrocarbon, one of the environmental carcinogens. Single nucleotide polymorphisms of CYP1A1 ; CYP1A1 3801T 1 C (CYP1A1 * 2A, CYP1A1 * 2B) are located in the 3 noncoding region and CYP1A1
Val) is a high metabolizer. The combination of CYP1A1 * 2A and CYP1A1 * 2B has been reported to increase the CYP1A1 inducibility [7] . However, in a recent study, a significant 3-fold decrease in expression was associated with the homozygous Msp I restriction fragment length polymorphism (CYP1A1 * 2A/ * 2A) [8] . The CYP1A1 3801T 1 C polymorphism was associated with a moderately to highly increased risk of lung cancer, and a 2455A 1 G polymorphism with a decreased risk of breast cancer in the Japanese [9] [10] [11] . The CYP1A1 polymorphism was also associated with lung cancer susceptibility in the Chinese [12] . However, the association of the CYP1A1 polymorphism with lung cancer has been the subject of controversy in Caucasians [13] [14] [15] . With regard to MM, a study on Caucasians has demonstrated that CYP1A1 polymorphisms are not associated with the MM risk [16] .
Glutathione S-transfersase (GST) is a phase II detoxifying enzyme that conjugates electrophilic intermediates metabolized by the phase I enzyme. It has been reported that the GSTT1 null genotype is associated with an increased risk for MM [16] .
The present study was designed to investigate the associations of CYP1A1 , GSTM1 and GSTT1 polymorphisms with the MM risk in a Korean population.
Patients and Methods

Study Population
The present case-control study was conducted using bone marrow samples archived on slides or peripheral blood samples from 116 Korean MM patients (male:female ratio, 78: 38; median age, 59 years; range, 30-81 years), who were diagnosed according to the criteria of the Southwest Oncology Group, and peripheral blood samples from 176 Korean controls (male:female ratio, 96: 80; median age, 49 years; range, 23-81 years). This research was approved by the Seoul National University College of Medicine/Seoul National University Hospital Institutional Review Board.
Genotyping CYP1A1 polymorphisms were determined using TaqMan allelic discrimination. Each reaction contained 10 ng of DNA template, 2.5 l of 2 ! TaqMan PCR Master Mix, 900 n M of each primer and 100 n M of each probe; the total volume was 5.0 l. Probes and primers used in TaqMan assays were as follows: for CYP1A1 2455A 1 G, forward primer: GCA TGG GCA AGC GGA A, reverse primer: GCC AGG AAG AGA AAG ACC TCC, FAM-TCG GTG AGA CCA TTG CCC G-TARMA, TET-CGG TGA GAC CGT TGC CCG C-TARMA, and for CYP1A1 3801T 1 C, forward primer: ACA GGG TCC CCA GGT CAT C, reverse primer: CCT GCG GCC CCA ACT AC, FAM-ACC TCC ACC TCC TGG GCT CAC A-TARMA, TET-AAC CTC CAC CTC CCG GGC TC-TARMA. PCR cycling reactions were performed in 384-well plates in a GeneAmp PCR system 9700 (Applied Biosystems, Foster City, Calif., USA). Amplification was started with initial denaturation at 95 ° C for 10 min followed by 40 cycles of denaturation at 95 ° C for 15 s and extension at 65 ° C for 1 min. After PCR, plates were read in an ABI Prism Sequence Detection System 7900HT (Applied Biosystems), and the results were analyzed using Sequence Detector Software version 2.0 (Applied Biosystems). Nomenclature of CYP1A1 polymorphisms followed the nomenclature system of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (http://www.cypalleles.ki.se/).
GSTM1 and GSTM1T1 polymorphisms were determined using multiplex PCR. GAPDH was amplified as an internal control. The PCR mixture consisted of genomic DNA, 2.5 mmol of dNTP, 2 l 10 ! PCR buffer, 1 U of Taq polymerase and primers (for GSTM1 , 5 -CTG CCC TAC TTG ATT GAT GG-3 , 5 -GAT TGT AGC AGA TCA TGC CC-3 , and for GSTT1, 5 -AGT TGC TCG AGG ACA AGT TC-3 , 5 -AGA TCT CCA GGA GGT GTT TG-3 ). Amplification was started with initial denaturation at 95 ° C for 10 min followed by 40 cycles of denaturation at 94 ° C for 30 s, annealing at 62 ° C for 30 s and extension at 72 ° C for 40 s. PCR products were analyzed with ethidium-bromide-stained 1.5% agarose gel. GSTM1 and GSTM1T1 null genotypes were determined by the presence or absence of a specific band for each genotype after PCR.
Statistics
The distribution of genotypes in the controls was tested for departure from the Hardy-Weinberg equilibrium. A risk for MM in Koreans was statistically analyzed by logistic regression, and the OR and 95% CI were adjusted by age and gender. The SPSS program (version 12.0; SPSS, Chicago, Ill., USA) was used for statistical analysis.
Results
The frequencies of CYP1A1 , GSTM1 and GSTT1 genotypes in the controls were all in accordance with the Hardy-Weinberg laws of equilibrium.
Association of the CYP1A1 Polymorphism with the MM Risk
The frequency of CYP1A1 * 1/ * 2A in MM patients was significantly lower than that in the controls, and the OR for CYP1A1 * 1/ * 2A to CYP1A1 * 1/ * 1 was 0.43 (95% CI, 0.19-0.98; p = 0.045), which showed a decreased risk for MM in this genotype ( table 1 ). The frequency of CYP1A1 * 1/ * 2B in MM patients was also significantly decreased. The OR for CYP1A1 * 1/ * 2B to CYP1A1 * 1/ * 1 was 0.51 (95% CI, 0.26-0.98; p = 0.043), which revealed a decreased risk for MM. Other CYP1A1 genotypes were not associated with MM.
For CYP1A1 alleles, the frequency of CYP1A1 * 2A was significantly lower in the MM patients than in the controls, and the OR for CYP1A1 * 2A to CYP1A1 * 1 was 0.57 (95% CI, 0.326-0.995; p = 0.048), which showed a decreased risk for MM. Other CYP1A1 alleles were not associated with MM.
Association of the GST Polymorphisms with MM
In the controls, the frequencies of GSTM1 null and GSTT1 null were 53.9 and 59.1%, respectively ( table 2 ). The genotypes of GSTM1 null and GSTT1 null were not significantly different between MM patients and the controls. The OR for GSTM1 null was 1.45 (95% CI, 0.86-2.44) and that for GSTT1 null was 0.85 (0.51-1.43). For GSTM1 and GSTT1 polymorphisms, no association with MM was observed.
Discussion
The present study showed that the CYP1A1 polymorphism is associated with a decreased risk for MM in Koreans, which is different from the previous report which suggested no association of CYP1A1 with MM in Caucasians [16] .
Allele frequencies of CYP1A1 * 1, * 2A and * 2B were similar in the Korean controls of the present study and those of a previous large-scale report on Asian controls (57.0, 15.9 and 27.2 vs. 62.5, 14.9 and 21.2%, respectively) [17] but different from those of Caucasian controls (89.0, 5.8 and 3.2%; n = 3,814; p ! 0.001). Taken together, CYP1A1 * 2A , which was found to be a low-risk group for MM in the present study, was more prevalent in Korean controls than in Caucasian controls (15.9 vs. 5.8%, respectively). We infer that the increased frequency of CYP1A1 * 2A in Asian controls compared to Caucasian controls (15.9 vs. 5.8%) can explain the lower incidence of MM in Asians. As another evidence for ethnic differences in the susceptibility to MM, we had previously reported that NQO1 * 2/ * 2 is associated with a decreased MM risk in Koreans (OR, 0.24; 95% CI, 0.01-0.68) [4] , while no significant association has been reported in Caucasians [6] . NQO1 * 2/ * 2, the low-risk group in our previous study [4] , is more prevalent in Korean controls than in Caucasian controls (19.9 vs. 1.5%; p ! 0.001; table 2 ), which may also explain the lower incidence of MM in Koreans. Both NQO1 and CYP1A1 are phase I enzymes that detoxify toxic compounds on the one hand and produce metabolic intermediates on the other hand. Considering that CYP1A1 * 2A/ * 2A and NQO1 * 2/ * 2 are low metabolizers [5, 8] , the protective effect of NQO1 * 2/ * 2 and CYP1A1 * 2A on MM implies that production of these metabolic intermediates might be involved in the pathogenesis of MM. In the present study, no significant associations of GSTM1 and GSTT1 polymorphisms with the risk for MM were found, in contrast to the report in which GSTT1 null is associated with an increased risk for MM in Caucasians [16] . The frequencies of GSTT1 null were rather higher in Korean controls than in Caucasian controls (59.1 vs. 14.1%, p ! 0.001), while those of GSTM1 showed no significant difference (53.9 vs. 53.7%; table 2 ). Unlike CYP1A1 * 2A and NQO1 * 2/ * 2 , the higher frequency of GSTT1 null in Korean controls did not contribute to MM development in Koreans. As an explanation of the lower incidence of MM in Korea in spite of the high prevalence of GSTT1 null, we infer that the genetic susceptibility to leukemia is the result of a concerted action of several metabolic enzyme polymorphisms and may not be explained by a single enzyme polymorphism.
It is well known that polymorphisms of metabolizing enzymes influence interindividual differences in susceptibility to malignancies, but it is unclear whether xenobiotic enzyme polymorphisms may explain ethnic differences in the incidence of MM. This study demonstrates that the CYP1A1 * 2A polymorphism is associated with a decreased MM risk in Koreans, whereas GSTM1 and GSTT1 polymorphisms are not associated with MM in Koreans. The low-risk groups of our study (CYP1A1 * 2A and NQO1 * 2/ * 2) were more prevalent in Korean controls than in Caucasian controls. The result of the present study suggested the difference in susceptibility to MM among ethnic groups, which may partly explain the lower incidence of MM in Koreans compared with Caucasians.
